Last reviewed · How we verify
NCT04451057: OSACA CATS
High Flow Nasal Cannula in Pediatric Patients After Cardiothoracic Surgery
NA trial testing high flow nasal cannula therapy in Pediatric Patients After Cardiothoracic Surgery in 286 participants. Status unknown.
20 February 2024
Quick facts
| Lead sponsor | Osaka University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 286 |
| Start date | 11 August 2020 |
| Primary completion | 20 February 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- high flow nasal cannula therapy
- low flow nasal cannula therapy
Conditions studied
- Pediatric Patients After Cardiothoracic Surgery — all drugs for Pediatric Patients After Cardiothoracic Surgery →
Sponsor
Osaka University
Who can join
Under 2, any sex, with Pediatric Patients After Cardiothoracic Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
High flow nasal cannula(HFNC) ventilation can provide such effects as wash-out effect of the carbon dioxide inside the anatomical dead space,some level of continuous airway pressure and humidified oxygen gases. Therefore because of its physiological benefits, it has been reported that HFNC can reduce "treatment failure" after extubation in pediatric patients like preterm babies,or infants who suffer from bronchitis. However there is no evidence showing that HFNC can reduce "treatment failure" after extubation in pediatric patients after cardiothoracic surgery. This multi-center randomized controlled trial (RCT) involving pediatric patients after cardiothoracic surgery will be conducted to determine whether HFNC,compared with conventional oxygen therapy,after extubation can reduce the rate of"escalation of care due to treatment failure".
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04451057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Osaka University trials
Trials by the same sponsor.
- NCT06924151 — Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients · NA · recruiting
- NCT06826027 — TAV-in-SAV in Japanese Patients · active not recruiting
- NCT06441994 — Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer · Phase 1 · recruiting
- NCT05939661 — A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer · Phase 2 · recruiting
- NCT05350098 — Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04451057 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Osaka University
- Last refreshed: 8 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing